Can rabies virus–neutralising antibody (RVNA) titres be measured after completing a rabies vaccination series?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 16, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Antibodies Be Measured After Rabies Vaccination?

Yes, rabies virus-neutralizing antibodies (RVNA) can be measured after vaccination, but routine post-vaccination serologic testing is not necessary for healthy immunocompetent individuals who complete the recommended vaccine series. 1

When Antibody Testing Is NOT Needed

Routine serologic testing is unnecessary for immunocompetent persons completing pre-exposure or postexposure prophylaxis because all healthy individuals tested 2-4 weeks after completing ACIP-recommended regimens have demonstrated adequate antibody responses. 1

  • In CDC studies, 100% of healthy persons who completed the recommended vaccination schedule according to guidelines showed protective antibody responses when tested. 1
  • The effectiveness of rabies vaccines is primarily measured by their ability to protect exposed persons, not by antibody titers alone, since other immune effectors beyond neutralizing antibodies contribute to protection. 1

When Antibody Testing IS Required

Immunosuppressed Patients

Immunosuppressed individuals must have their rabies virus-neutralizing antibody titers checked after completing vaccination. 1

  • Patients immunosuppressed by disease (HIV, chronic lymphoproliferative leukemia) or medications (corticosteroids, other immunosuppressive agents, antimalarials) require mandatory serologic testing. 1
  • Testing should occur 1-2 weeks after completing the vaccine series (or 7-14 days after the final dose). 1
  • Specimens should completely neutralize challenge virus at a 1:5 serum dilution by the Rapid Fluorescent Focus Inhibition Test (RFFIT). 1
  • Failures to seroconvert after the third dose should be managed in consultation with appropriate public health officials. 1

High-Risk Occupational Groups

Persons at continuous or frequent risk for rabies exposure require periodic antibody monitoring to ensure ongoing immune response. 1

  • Continuous-risk category (laboratory workers handling live rabies virus): Serum should be tested for rabies antibody every 6 months. 1
  • Frequent-risk category (veterinarians, animal control officers, wildlife officers in rabies-endemic areas): Serum should be tested every 2 years. 1
  • If the titer falls below the minimum acceptable level (complete neutralization at 1:5 dilution), a single pre-exposure booster dose is recommended. 1

Testing Methodology and Interpretation

When titers are obtained, specimens collected 1-2 weeks after pre-exposure or postexposure prophylaxis should completely neutralize challenge virus at a 1:5 serum dilution by the RFFIT. 1

  • This dilution is approximately equivalent to the WHO minimum titer of 0.5 IU/mL. 1
  • Antibody titers vary with time since the last vaccination, and small differences (within one dilution) may occur among laboratories performing RFFIT. 1
  • Rabies antibody titer determination tests not approved by FDA are inappropriate substitutes for RFFIT because discrepant results have been observed. 1

Important Caveats

Antibody levels do not definitively determine a person's immune status—they are markers of continuing immune response, not absolute predictors of protection. 1

  • In animal studies, neutralizing antibody titers have been shown to be imperfect markers of protection. 1
  • No "protective" titer threshold is definitively known, and other immune effectors beyond neutralizing antibodies are operative in disease prevention. 1
  • Two years after primary pre-exposure vaccination, 93-98% of persons who received the three-dose series intramuscularly maintain complete neutralization at 1:5 dilution. 1

Common Pitfalls to Avoid

  • Do not delay postexposure prophylaxis to obtain antibody titers in previously unvaccinated persons—this is inappropriate and dangerous. 1
  • Do not use antibody testing to decide whether previously vaccinated persons need prophylaxis after re-exposure; determining titers for decision-making is inappropriate because several days are required for results, no protective titer is definitively known, and other immune components contribute to protection. 1
  • State or local health departments or CDC can provide names and addresses of laboratories performing appropriate rabies virus-neutralizing serologic testing. 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Does a patient who completed an antirabies (rabies) vaccination series need another full course of antirabies (rabies) vaccination after being bitten again?
What rabies vaccine doses are recommended for a patient who has previously received the first 4 doses of intramuscular (IM) rabies vaccine and is now exposed to a new potential rabies source through a cat bite?
Is the rabies (Rabies virus) vaccine effective for a previously vaccinated, immunocompetent individual if administered 5 days after exposure?
Do I need a booster dose of the rabies (Rabies Virus Vaccine) vaccine after being bitten again, one month after initial vaccination?
What is the next step for a patient who was bitten by a dog, received rabies shots (Post-Exposure Prophylaxis (PEP)), but has rabies antibody titers (Rabies Ab (Antibody)) below detection?
What maternal BMI (kg/m²) threshold warrants diabetes mellitus screening at the first prenatal visit?
How is Clostridioides difficile infection classified by severity and what are the recommended treatments for mild‑to‑moderate, severe, fulminant, and recurrent disease?
When should anti‑tuberculosis therapy be initiated in patients with active or latent tuberculosis, including special populations such as pregnant women and those with suspected drug‑resistant disease?
In an adult patient on nifedipine (30–90 mg daily) for hypertension who now has a new or worsening pericardial effusion, how should the effusion be evaluated and treated, and what alternative antihypertensive therapy is recommended?
Can I get surgical outpatient department (OPD) cases that represent typical everyday presentations for use as case‑based questions?
Is sulfasalazine an appropriate treatment for a low‑grade hormone‑dependent carcinoma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question